X4 Pharmaceuticals Announces Director and Officer Changes
Ticker: XFOR · Form: 8-K · Filed: Aug 25, 2025 · CIK: 1501697
| Field | Detail |
|---|---|
| Company | X4 Pharmaceuticals, Inc (XFOR) |
| Form Type | 8-K |
| Filed Date | Aug 25, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
X4 Pharma board shake-up, exec comp changes effective Aug 22.
AI Summary
On August 22, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the departure of certain officers and directors, alongside the election of new board members and adjustments to executive compensation arrangements. These changes are effective as of August 22, 2025.
Why It Matters
Changes in a company's board and executive team can signal shifts in strategy, operational focus, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate underlying issues or strategic realignments that may affect the company's future performance and stock price.
Key Numbers
- 001-38295 — SEC File Number (Identifies the company's filing history with the SEC.)
- 27-3181608 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- X4 Pharmaceuticals, Inc. (company) — Registrant
- August 22, 2025 (date) — Effective date of changes
- Delaware (jurisdiction) — State of incorporation
- Boston, Massachusetts (location) — Principal executive offices
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates the departure of 'certain officers' and 'directors' but does not specify the exact roles or names of those departing in this summary section.
Who are the newly elected directors or appointed officers?
The filing mentions the election of directors and appointment of officers but does not list their names or specific positions in the provided text.
What are the details of the compensatory arrangements for certain officers?
The filing notes changes to 'Compensatory Arrangements of Certain Officers' but does not provide specific details on the nature or value of these arrangements in the excerpt.
What is the significance of the date 'August 22, 2025' in this filing?
August 22, 2025, is the date of the earliest event reported and the effective date for the changes in directors, officers, and compensation arrangements.
What was X4 Pharmaceuticals, Inc. formerly known as?
X4 Pharmaceuticals, Inc. was formerly known as Arsanis, Inc., with a name change date of September 20, 2010.
Filing Stats: 481 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-08-25 08:12:48
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market
Filing Documents
- xfor-20250822.htm (8-K) — 26KB
- 0001501697-25-000008.txt ( ) — 144KB
- xfor-20250822.xsd (EX-101.SCH) — 2KB
- xfor-20250822_lab.xml (EX-101.LAB) — 23KB
- xfor-20250822_pre.xml (EX-101.PRE) — 13KB
- xfor-20250822_htm.xml (XML) — 3KB
From the Filing
xfor-20250822 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 X4 PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38295 27-3181608 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 61 North Beacon Street, 4th Floor Boston, Massachusetts 02134 (Address of principal executive offices) (Zip Code) ( 857 ) 529-8300 (Registrant's telephone number, including area code) Not applicable (Former name or former address, if changed since last report) _______________________________________________________________________________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 22, 2025, David McGirr and R. Keith Woods resigned from the board of directors (the "Board") of X4 Pharmaceuticals, Inc. (the "Company"), including all committees thereof, effective immediately. The resignations of Mr. McGirr and Mr. Woods from the Board are not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. In connection with the resignations of Messrs. McGirr and Woods, Michael Wyzga was appointed to serve as chair of the audit committee of the Board (the "Audit Committee") and Francoise de Craecker and Gary Bridger were appointed to serve as members of the Audit Committee. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. X4 PHARMACEUTICALS, INC. Date: August 25, 2025 By: /s/ David H. Kirske Name: David H. Kirske Title: Chief Financial Officer